News articles about AnaptysBio (NASDAQ:ANAB) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AnaptysBio earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.8571674943688 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of AnaptysBio (NASDAQ:ANAB) opened at $88.75 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.77 and a current ratio of 10.77. AnaptysBio has a fifty-two week low of $15.17 and a fifty-two week high of $90.80.
AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02. equities analysts expect that AnaptysBio will post -1.72 earnings per share for the current fiscal year.
A number of brokerages have commented on ANAB. SunTrust Banks began coverage on shares of AnaptysBio in a research note on Wednesday, November 15th. They set a “buy” rating and a $115.00 price target for the company. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective for the company in a report on Friday, November 10th. Jefferies Group started coverage on shares of AnaptysBio in a report on Thursday, November 9th. They set a “buy” rating and a $101.00 price objective for the company. Wedbush reaffirmed a “positive” rating and set a $82.00 price objective (up previously from $75.00) on shares of AnaptysBio in a report on Tuesday, November 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $76.00 price objective (up previously from $35.00) on shares of AnaptysBio in a report on Friday, October 13th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $84.78.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/12/15/anaptysbio-anab-receives-daily-news-sentiment-score-of-0-07.html.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.